Experimental hepatitis b drug trial halted midway

NCT ID NCT02604212

Terminated Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ARC-520 in 32 adults with chronic hepatitis B who were already taking antiviral medications (entecavir or tenofovir). The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more than placebo. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Locations

Research Site 1

Hong Kong, 999077, China
Research Site 10

Leipzig, 04103, Germany
Research Site 11

Frankfurt, 60590, Germany
Research Site 12

Yangsan-si Gyeongnam, 626-770, South Korea
Research Site 13

Busan, 602-739, South Korea
Research Site 14

Seoul, 110-744, South Korea
Research Site 15

Incheon, 405-760, South Korea
Research Site 16

Seoul, 120-752, South Korea
Research Site 2

Hong Kong, China
Research Site 3

Tübingen, 72076, Germany
Research Site 4

Leipzig, 4103, Germany
Research Site 5

München, 81377, Germany
Research Site 6

Ulm, 89081, Germany
Research Site 7

Würzburg, 97080, Germany
Research Site 8

Hanover, 30625, Germany
Research Site 9

Hamburg, 20099, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.